Identification of the human cytochrome P450s responsible for the in vitro metabolism of a leukotriene B4 receptor antagonist, CP-195,543

References

• BUTLER, M. A., GUENGERICH, F. P. and KADLUBAR, F. F., 1989, Metabolic oxidation of the carcinogens 4-aminobiphenyl and 4,4'-methylenebis(2-chloroaniline) by human hepatic microsomes and by purified rat hepatic cytochrome P-450 monooxygenases. Cancer Research, 49, 25–31.
   PubMed Web of Science ®Google Scholar
• CARLOS, T. M. and HARLAN, J. M., 1994, Leukocyte-endothelial adhesion molecules. Blood, 84, 2068–2101.
   PubMed Web of Science ®Google Scholar
• CROOKS, S. W. and STOCKLEY, R. A., 1998, Leukotriene B4. International Journal of Biochemistry and Cell Biology, 30, 173–178.
   PubMed Web of Science ®Google Scholar
• DALVIE, D. K. and O'DONNELL, J. P., 1999, Metabolism of CP-195,543, a leukotriene B4 receptor antagonist, in the Long—Evans rat and cynomolgus monkey. Xenobiotica, 29,1123–1140.
   Google Scholar
• DOMANSKI, D. L., FINTA, C., HALPERT, J. R. and ZAPHIROPOULOS, P. G., 2001, cDNA cloning and initial characterization of cYP3A43, a novel human cytochrome P450. Molecular Pharmacology, 59, 386–392.
   PubMed Web of Science ®Google Scholar
• FORD-HUTCHINSON, A. W., BRAY, M. A., DOIG, M. V., SHIPLEY, M. E. and SMITH, M. J. H., 1980, Leukotriene B, a potent chemokinetic and aggregating substance released from polymorpho-nuclear leukocytes. Nature (London), 286, 264–265.
   Google Scholar
• GELLNER, K., EISELT, R., HUSTERT, E., ARNOLD, H. KOCH, I., HABERL, M., DEGLMANN, C. J., BURR, 0., BUNTEFUSS, D. and ESCHER S., 2001, Genomic organization of the human CYP3A locus: identification of a new, inducible CYP3A gene. Pharmacogenetics, 11, 111–121.
   Google Scholar
• GUENGERICH, F. P., 2000, Pharmacogenomics of cytochrome P450 and other enzymes involved in biotransformation of xenobiotics. Drug Development Research, 49, 4–16.
   Web of Science ®Google Scholar
• KRONBACH, T., MATHYS, D., GUT, J., CATIN, T. and MEYER, U. A., 1987, High-performance liquid chromatographic assays for bufuralol V-hydroxylase, debrisoquine 4-hydroxylase, and dextromethorphan 0-demethylase in microsomes and purified cytochrome P-450 isozymes of human liver. Annals of Biochemistry, 162, 24–32.
   Google Scholar
• LI, A. P., KAMINSKY, D. L. and RASMUSSEN, A., 1995, Substrate of human hepatic cytochrome P450 3A4. Toxicology, 104, 1–8.
   PubMed Web of Science ®Google Scholar
• LIN, J. H., CHIBA, M. and BAILLIE, T. A., 1999, Is the role of the small intestine in first-pass metabolism overemphasized? Pharmacology Reviews, 51,135–158.
   Google Scholar
• LIN, J. H. and Lu, A. Y., 1998, Inhibition and induction of cytochrome P450 and the clinical implication. Clinical Pharmacokinetics, 35, 361–390.
   PubMed Web of Science ®Google Scholar
• MEIER, U. T, KRONBACH, T. and MEYER, U. A., 1985, Assay of mephenytoin metabolism in human liver microsomes by high-performance liquid chromatography. Annals of Biochemistry, 151, 286–291.
   Google Scholar
• MINERS, J. 0., SMITH, K. J., ROBSON, R. A., McMaNus, M. E., VERONESE, M. E. and BIRKETT, D. J., 1988, Tolbutamide hydroxylation by human liver microsomes. Kinetic characterization and relationship to other cytochrome P-450 dependent xenobiotic oxidations. Biochemical Pharmacology, 37, 1137–1144.
   Google Scholar
• OMURA, T. and SATO, R., 1964, The carbon monoxide binding pigment of liver microsmes. Journal of Biological Chemistry, 239, 3137–3142.
   Google Scholar
• ORTIZ DE MONTELLANO, P., Mico, B. A., MATHEWS, J. M., KUNZE, K. L., MIWA, G. T. and Lu, A. Y. H., 1981, Selective inactivation of cytochrome P-450 isozymes by suicide substrates. Archives of Biochemistry and Biophysics, 210, 717–728.
   Google Scholar
• PRAKASH, C., KAMEL, A., Cm, D., WHALEN, R. D., MICELI, J. and TWEEDIE, D., 2000, Identification of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions. British Journal of Clinical Pharmacology, 49(suppl.), 35S–42S.
   Google Scholar
• SHOWELL, H. J., CONKLYN, M. J., ALPERT, R., HINGORANI, G. P., WRIGHT, K. F., SMITH, M. A., STAM, E., SALTER, E. D., SCAMPOLI, D. N., MELTZER, S., REITER, L. A., KOCH, K., PISCOPIO, A. D., CORTINA, S. R., LOPEZ-ANAYA, A., PETTIPHER, E. R., MILICI, A. J. and GRIFFITHS, R. J., 1998, The preclinical pharmacological profile of the potent and selective leukotriene B4 antagonist CP-195,543. Journal of Pharmacology and Experimental Therapeutics, 285, 946–954.
   Google Scholar
• SONDERFAN, A. J., ARLOTTO, M. P., DUTTON, D. R., MCMILLEN, S. K. and PARKINSON, A., 1987, Regulation of testosterone hydroxylation by rat liver microsomal cytochrome P-450. Archives of Biochemistry and Biophysics, 255, 27–41.
   PubMed Web of Science ®Google Scholar
• THUMMEL, K. E. and WILKINSON, G., 1998, In vitro and in vivo drug interactions involving human CYP3A. Annual Reviews in Pharmacology and Toxicology, 38, 389–430.
   PubMed Web of Science ®Google Scholar
• WILLIAMS, J. A., RING, B. J., CANTRELL, V. E., JONES, D. R., ECKSTEIN, J., RUTERBORIES, K, HAMMAN, M. A., HALL, S. D. and WRIGHTON, S. A., 2002, Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metabolism and Disposition, 30, 883–891.
   PubMed Web of Science ®Google Scholar
• WRIGHTON, S. A., VANDENBRANDEN, M. and RING, B. J., 1996, The human drug metabolizing cytochrome P450. Journal of Pharmacokinetics and Biopharmacology, 24, 461–473.
   PubMedGoogle Scholar